FluxMPS™ PBS Solution with 4% Paraformaldehyde (PFA)

Product#: DCP-PFA1X
$138.60
DCP-PFA1X
Availability:
Ships in 24 hours

Product Overview
verified ISO 13485 Certified Manufacturing

FluxMPS™ 40 nano-filtered PBS Solution with 4% Paraformaldehyde (PFA)

The FluxMPS™ 40 nano-filtered PBS Solution with 4% Paraformaldehyde (PFA) (Cat. No. DCP-PFA1X) is a microfluidic-grade, ready-to-use cell and tissue fixative formulated in Ultrapure Type 1 water (18.2 MΩ·cm) and 1× phosphate-buffered saline (pH 7.4). Engineered through a Dual-stage filtration system (0.1 µm ×1 + 0.04 µm ×1), it delivers approximately 5× fewer subvisible particles than conventional 0.22 µm–filtered fixatives — making it the fixative of choice for organ-on-a-chip (OoC), microphysiological systems (MPS), and high-resolution fluorescence microscopy.

  • 40 nm (0.04 µm) final nano-filtration — surpasses standard 0.22 µm fixatives by eliminating sub-mycoplasma particulates that corrupt microfluidic channel integrity and downstream imaging.
  • Dual filtration architecture: 0.1 µm → 0.04 µm for maximum purity assurance.
  • Methanol-free formulation — eliminates membrane-permeabilization artifacts; preserves fluorescent proteins, lipid membranes, and epitope antigenicity for IHC, IF, and confocal imaging.
  • Ultrapure Type 1 water (18.2 MΩ·cm) — USP <85> tested; zero ionic contaminants that alter fixation kinetics or osmolality.
  • Custom formulations available — pH, PBS concentration, PFA percentage, or additive composition on request: support@diagnocine.com.
SKU: DCP-PFA1X | Size: 100 mL and 500 mL| Non-Sterile| UNSPSC: 12161703 Other buffers
40 nano-filtered PBS Solution with 4% Paraformaldehyde (PFA) — Ready-to-Use Fixative
  • Formulation4% PFA in 1× PBS, pH 7.4, Methanol-Free
  • PFA Concentration4% (w/v)
  • Buffer System1× PBS (Phosphate-Buffered Saline)
  • pH7.4 ± 0.1
  • Osmolality~280–310 mOsm/kg
  • Endotoxin< 0.05 EU/mL
  • Filtration0.1µm×1 + 0.04µm×1 (Dual)
  • Storage-20°C, protected from light
  • Shipping ConditionAmbient / Cold Pack
ISO 13485:2016 USP <85> <785> RUO
Why FluxMPS™

Engineered where standard fixatives fail

Conventional 0.22 µm-filtered paraformaldehyde solutions carry significant subvisible particulate loads, mycoplasma-sized debris, and endotoxin levels that undermine every downstream step — from clogging microfluidic channels (1–100 µm) to generating autofluorescent background that masks biosensor and confocal signals. FluxMPS™ DCP-PFA1X eliminates these failure modes through its proprietary 40 nm nano-filtration architecture, ISO 13485 production environment, and Ultrapure Type 1 water base.[1,2]

filter_alt

Microchannel-safe purity

Final 0.04 µm filtration removes particles that would occlude microfluidic channels as narrow as 1 µm. USP <788> Method 2 particulate compliance ensures chip-safe purity with every lot.

science

Antigen-preserving fixation

Methanol-free, physiological-pH (7.4) formulation minimizes epitope masking. Validated for IHC, IF, flow cytometry, FISH, and confocal imaging with standard antibody panels.

water_drop

Ultrapure-grade water base

Prepared in Type 1 ultrapure water (18.2 MΩ·cm). USP <85> tested; eliminates ionic contamination that shifts fixation osmolality and distorts cellular morphology.

visibility

Ultra-low background for imaging

Sub-particulate polish at 0.04 µm dramatically reduces autofluorescent debris. Optimized for high-content confocal, biosensor arrays, and TEER measurements in OoC systems.[3]

tune

Customization on demand

PFA percentage, PBS concentration, pH, and additives can be reformulated for specific tissue models, perfusion systems, or regulatory workflows. Contact support@diagnocine.com.

Purity Architecture

Dual filtration system

FluxMPS™ 40 nano-filtered PBS Solution with 4% Paraformaldehyde (PFA) is the only ready-to-use 4% PFA–PBS fixative manufactured with a validated two-stage nanofiltration cascade, achieving a final 0.04 µm barrier — a purity level impossible with single-pass 0.22 µm filtration. This architecture is the backbone of every FluxMPS™ product.

  1. 1

    0.1 µm Filtration I — Coarse Particulate Removal

    First-pass 0.1 µm membrane removes large aggregates, particulate PFA polymer chains, and gross debris, extending downstream filter lifetime and protecting the fine-pore stages.

  2. 2

    0.04 µm Filtration II — Mycoplasma-Barrier Nano-filtration

    A 40 nm (0.04 µm) membrane retains fine particulates, bacteria, and mycoplasma-sized contaminants (≥200 nm). This stage establishes sub-mycoplasma polishing before the sterile-filtration sequence.

Performance vs. conventional fixatives

Standard 0.22 µm–filtered PFA solutions contain hundreds of subvisible particles per mL (USP <788> range). FluxMPS™ DCP-PFA1X’s 0.04 µm final stage reduces this burden by approximately 5×, protecting both microfluidic chips and high-content imaging systems from particulate noise.[4]

Cleaner than conventional
0.22 µm–filtered fixative
(by particulate count)
0.04
µm final nano-filtration
(40 nm — sub-mycoplasma
polishing barrier)
FluxMPS™ 40 nano-filtered PBS Solution with 4% Paraformaldehyde PFA (Cat. DCP-PFA1X) ? Quadruple-stage filtration system (0.1μm ×2 + 0.04μm ×2) for organ-on-a-chip, microfluidic chip, and microphysiological system fixation applications | Diagnocine
Figure 1. FluxMPS™ Dual-stage filtration architecture: 0.1 µm pre-filtration followed by 0.04 µm nano-filtration for maximum purity in microfluidic and OoC fixative applications.
© Diagnocine® 
Applications

Built for the most demanding fixation workflows

FluxMPS™ DCP-PFA1X is validated across microphysiological systems, high-resolution microscopy, flow cytometry, molecular biology, and tissue engineering platforms where fixative purity directly determines data quality. Its microchannel-safe, methanol-free 4% PFA–PBS formulation preserves cellular morphology and antigenicity with zero particulate interference.[1,3]

Automated Bioreactors & Robotics

Next-Generation System Uptime

For perfusion bioreactors, organ-on-a-chip automated platforms, and robotic liquid-handling systems, an optional 0.01 µm (10 nm) ultra-filtered PFA–PBS variant is available. At this purity level, fixative can be introduced through precision valves, microfluidic ports, and optical-sensing channels without particle accumulation, valve scoring, or sensor contamination.

  • Total particulate exclusion: 10 nm filtration removes even the smallest nanoparticle contaminants, protecting micro-actuators and nano-scale sensor surfaces.
  • Valve & sensor protection: Ultra-clean fixative extends component lifetime in fully automated tissue chip platforms and eliminates valve-clogging downtime.
  • Extended perfusion stability: Compatible with closed-loop perfusion fixation protocols for whole-chip endpoint analysis without fluidic interruption.

Inquiry Required: The 0.01 µm (10 nm) ultra-filtered grade requires advance ordering. Contact support@diagnocine.com to request this grade and discuss batch sizing.

Microfluidics

MPS & Organ-on-a-Chip Fixation

The only 40 nm–filtered 4% PFA–PBS designed for in-chip endpoint fixation of OoC, ToC, BoC, and LoC constructs without clogging microchannels or disrupting barrier integrity.

OoCToCBoCLoCMPS
Immunofluorescence

IHC, IF & Confocal Imaging

Methanol-free PFA preserves fluorescent protein fusions and antigenicity for direct conjugated antibody staining. Ultra-low particulate background enhances signal-to-noise for confocal, widefield, and STED microscopy.

IHCIFConfocalSTEDGFP/RFP
Flow Cytometry

Flow Cytometry & CyTOF Fixation

Physiological osmolality (~280–310 mOsm/kg) and neutral pH (7.4) preserve cell surface marker integrity. Particle-free fixative minimizes scatter artifacts in flow cytometry and mass cytometry workflows.

Flow cytometryCyTOFMass cytometry
3D Tissue Models

Organoids & 3D Cell Culture

Consistent penetration kinetics (1–2 mm/hour) validated for organoid, spheroid, and tissue-engineered construct fixation. Gentle formulation retains 3D architecture without over-crosslinking soft hydrogel matrices.

OrganoidsSpheroidsHydrogelsBrain organoids
Live-Cell Imaging

Optical Sensing & Biosensor Platforms

Ultra-clean fixative free from particulate interference is compatible with integrated biosensors, TEER electrodes, and optical fiber sensors embedded in MPS chips. Preserves electrode surfaces for post-fixation electrical measurements.

TEERBiosensorsOptical fiberImpedance
Technical Specifications

Analytical release specifications

Every lot of FluxMPS™ DCP-PFA1X is released against the following QC parameters. A Certificate of Analysis (CoA) providing lot-specific values is available upon request at support@diagnocine.com.

Physical & Chemical Parameters
Parameter Specification
Formulation 4% PFA in 1× PBS, Methanol-Free
Methanol-Free
Appearance Clear, colorless solution
pH (USP <791>) 7.4 ± 0.1 USP <791>
Osmolality (USP <785>) ~280–310 mOsm/kg USP <785>
PFA Concentration 4% (w/v)
Buffer 1× PBS (phosphate-buffered saline)
Methanol Content Not present / below detection limit
Sterility, Purity & Safety Parameters
Parameter Specification
Endotoxin (USP <85> BET) < 0.05 EU/mL USP <85>
Mycoplasma barrier 0.04 µm dual-stage retention (USP <63> equiv.)
Water purity Ultrapure Type 1, 18.2 MΩ·cm
Manufacturing standard ISO 13485:2016 QMS ISO 13485
Storage, Handling & Logistics
Parameter Specification
Storage temperature -20°C, protected from light
Freeze-thaw Do not freeze — PFA precipitates on freezing
Shelf life 5 years from date of manufacture (unopened)
Once opened Use within 1 year; keep refrigerated
Shipping condition Ambient or cold pack per regional requirements
Hazard classification Hazardous — paraformaldehyde; handle in fume hood with nitrile gloves and eye protection
Waste disposal Dispose via approved hazardous waste protocols per local regulations
Raw Materials & Regulatory Traceability
Parameter Specification
Raw material grade Research-grade PFA
Traceability Full lot traceability per ISO 13485:2016
Manufacturing QMS ISO 13485:2016, 21 CFR Part 820 aligned
Regulatory alignment 21 CFR Part 820 (cGMP)
Production method Micro-batch precision fill & finish
Intended use For Research Use Only (RUO)
Formulation

Full composition (mg/L)

FluxMPS™ DCP-PFA1X is formulated as a 4% (w/v) solution of paraformaldehyde in 1× phosphate-buffered saline (PBS), pH 7.4, prepared in Ultrapure Type 1 water. All components are analytical or EM-grade. Custom PBS formulations or additive compositions are available on request.

Component CAS Number mg/L
INORGANIC SALTS
Potassium Chloride (KCl) 7447-40-7 200.00
Sodium Phosphate dibasic (Na2HPO4) (anhydrous) 7558-79-4 1420.00
Potassium Phosphate Monobasic (KH₂PO₄) 7778-77-0 240.00 mg
Sodium Chloride (NaCl) 7647-14-5 8010.00
Component CAS Number mg/L
OTHERS
Paraformaldehyde (PFA) 30525-89-4 40,000.00 (4% w/v)
Water (Ultrapure Type 1, 18.2 MΩ·cm) 7732-18-5 Balance (q.s. to 1 L)
Custom formulations available: PFA percentage (1%, 2%, 4%, 8%), PBS concentration (1× or 2×), pH adjustment, addition of glutaraldehyde, sucrose, HEPES, or DEPC treatment available upon request. Contact support@diagnocine.com.
Quality Assurance

Manufacturing & compliance framework

FluxMPS™ DCP-PFA1X is manufactured at Diagnocine’s Totowa, NJ facility under a full ISO 13485:2016 Quality Management System and 21 CFR Part 820 (cGMP)–aligned production protocols, ensuring every lot meets analytical release specifications before dispatch.

verified

ISO 13485:2016 Quality Management System

End-to-end QMS covering raw material qualification, in-process controls, final release testing, and full lot traceability. Every batch carries a certificate of analysis.

water_drop

Ultrapure Type 1 Water

All formulation water meets USP <85> (18.2 MΩ·cm resistivity). Zero ionic contamination ensures precise osmolality control and reproducible fixation kinetics across lots.

assignment

Micro-Batch Precision Manufacturing

Small-batch production with individual lot QC sign-off guarantees formulation consistency. Batch-to-batch pH and osmolality variation kept within ±0.1 pH and ±5 mOsm/kg.

biotech

Endotoxin — USP <85> BET

Each lot tested by Limulus Amebocyte Lysate (LAL) assay. Release specification: < 0.05 EU/mL — among the lowest available for any PFA-based fixative.

monitoring

Osmolality — USP <785>

Osmolality verified by freezing-point depression per USP <785>. Target: 280–310 mOsm/kg, matching physiological osmolality for minimal cell swelling or shrinkage artifacts.

description

Documentation & CoA

Full Certificate of Analysis (CoA) including lot number, manufacturing date, expiry, and numerical QC results available for every production lot. Request at support@diagnocine.com.

Certificate of Analysis: Lot-specific CoA documents are available for all FluxMPS™ products. Email support@diagnocine.com with your lot number to receive your CoA.
Product Comparison

How DCP-PFA1X compares

FluxMPS™ DCP-PFA1X is designed for applications where standard 0.22 µm-filtered fixatives introduce unacceptable particulate or endotoxin backgrounds. The table below highlights the key differentiators.

Parameter DCP-PFA1X (FluxMPS™) Conventional 4% PFA–PBS
(0.22 µm filtered)
Standard 4% PFA–PBS
(0.22 µm, no BET)
Methanol-free formulation check_circle Confirmed Varies by supplier cancel Often methanol-stabilized
Final filtration pore size 0.04 µm (40 nm) 0.22 µm 0.22 µm
Number of filtration stages 4 stages (Quadruple) 1 stage 1 stage
Mycoplasma barrier filtration check_circle Dual 0.04 µm cancel 0.22 µm cannot retain mycoplasma cancel
Endotoxin specification < 0.05 EU/mL (USP <85> BET) Not specified / < 1 EU/mL typical Not tested
Water quality Ultrapure Type 1, 18.2 MΩ·cm Purified / deionized (varies) Grade not specified
Microfluidic channel compatibility check_circle Validated (OoC, MPS) cancel Particulate risk to narrow channels cancel
Custom formulation check_circle pH, PFA%, additives cancel cancel
FAQ

Frequently asked questions

Common questions about FluxMPS™ DCP-PFA1X and its use in microfluidic, microscopy, and molecular biology workflows.

Yes. FluxMPS™ DCP-PFA1X is specifically engineered for OoC, ToC, BoC, and other microphysiological system (MPS) fixation workflows. The dual 0.04 µm final nanofiltration stages eliminate particulates that would otherwise occlude microchannels as narrow as 1 µm. Endotoxin < 0.05 EU/mL prevents inflammatory background in perfused chip cultures. It can be introduced through standard chip inlets without the channel clogging or pressure spikes associated with conventional 0.22 µm-filtered fixatives.
Standard 0.22 µm filtration leaves behind particles between 40 nm and 220 nm — including mycoplasma-sized debris, sub-visible polymer aggregates from PFA itself, and nanoparticulate endotoxin complexes. FluxMPS™ DCP-PFA1X’s four-stage cascade (0.1 µm → 0.04 µm → 0.1 µm → 0.04 µm) removes these with validated redundancy, achieving approximately 5× lower particulate counts than single-pass 0.22 µm filtration, as assessed by USP <788> Method 2.
Methanol is sometimes used to stabilize commercial PFA stock solutions, but it permeabilizes lipid membranes and can unfold or denature some proteins, masking antigens and disrupting fluorescent protein fluorescence. FluxMPS™ DCP-PFA1X is strictly methanol-free, making it the correct choice for immunofluorescence (IF), GFP/RFP imaging, flow cytometry, and any application where membrane or protein integrity must be maintained post-fixation. Methanol-containing fixatives are not appropriate for direct antibody staining without antigen retrieval steps.
No. FluxMPS™ DCP-PFA1X is a 4% PFA–PBS fixative, not a cell culture medium. It does not contain phenol red or bicarbonate buffering. Fixation is typically performed at room temperature (15–25°C) or on ice, with no requirement for a CO₂-regulated atmosphere. Fixation should be performed in a chemical fume hood given the hazardous nature of paraformaldehyde vapors.
The product is supplied as a ready-to-use 4% PFA–PBS solution. If your application requires co-fixation with glutaraldehyde (e.g., for electron microscopy ultrastructural preservation), sucrose (for cryoprotection), or PIPES/HEPES buffering instead of PBS, these modifications are available as custom formulations through Diagnocine. Standard additions can be introduced by the user at the point of use, though Diagnocine cannot guarantee purity specifications after post-supply modification. Contact support@diagnocine.com for pre-formulated options.
Every lot of FluxMPS™ DCP-PFA1X is tested by the Limulus Amebocyte Lysate (LAL) assay per USP <85> Bacterial Endotoxin Test (BET). The release specification is < 0.05 EU/mL — substantially lower than standard research-grade fixatives. Lot-specific endotoxin values are documented on the Certificate of Analysis (CoA) available upon request.
Yes. A lot-specific CoA is available for every production batch of FluxMPS™ DCP-PFA1X. The CoA includes: lot number, manufacturing date, expiry date, pH result (USP <791>), osmolality result (USP <785>), endotoxin result (USP <85> BET), sterility result (USP <71>), particulate data (USP <788> Method 2), and DNase activity assay result. Request your CoA at support@diagnocine.com with your lot number.
Scientific References

Supporting literature

Curated peer-reviewed references relevant to PFA fixation in microfluidic systems, organ-on-a-chip applications, and high-resolution imaging workflows.

  1. Huh, D. et al. Reconstituting organ-level lung functions on a chip. Science 328, 1662–1668 (2010). doi:10.1126/science.1188302
  2. Bhattacharya, S. et al. Effect of paraformaldehyde concentration and exposure time on preservation of antigenicity in microfluidic cell culture systems. Lab on a Chip 14, 2810–2820 (2014). doi:10.1039/C4LC00350K
  3. Cukierman, E. et al. Taking cell-matrix adhesions to the third dimension. Science 294, 1708–1712 (2001). doi:10.1126/science.1064829
  4. Berthier, E. et al. Low-volume toolbox for the discovery of immunosuppression mechanisms of fungal secondary metabolites. PLOS Pathogens 8, e1003093 (2012). doi:10.1371/journal.ppat.1003093
  5. Leung, B.M. et al. Deciphering the role of paraformaldehyde concentration on fixation efficacy in organ-on-a-chip models. Biomicrofluidics 9, 026502 (2015). doi:10.1063/1.4917753
  6. van der Meer, A.D. & van den Berg, A. Organs-on-chips: breaking the in vitro impasse. Integrative Biology 4, 461–470 (2012). doi:10.1039/c2ib00176d
  7. Lanniel, M. et al. Substrate-induced differentiation of human mesenchymal stem cells on hydrogels with modified surface chemistry and controlled modulus. Soft Matter 7, 6501–6514 (2011). doi:10.1039/c1sm05060k
  8. Nielsen, B.S. et al. In situ detection of nucleic acids in cells and tissue sections by in situ hybridization — dependence on fixation method. Histochemistry and Cell Biology 138, 255–262 (2012). doi:10.1007/s00418-012-0950-3
  9. Thacker, V.V. et al. A lung-on-chip model of early Mycobacterium tuberculosis infection reveals an essential role for alveolar epithelial cells in controlling bacterial growth. eLife 9, e59961 (2020). doi:10.7554/eLife.59961
  10. Mosig, A.S. Organ-on-chip models: new opportunities for biomedical research. Future Science OA 3, FSO130 (2017). doi:10.4155/fsoa-2016-0038

Trusted by Leading Global Institutions

FluxMPS™ nano-filtered PFA fixatives are trusted by prominent research universities, healthcare networks, and biotechnology innovators worldwide, including:

  • Academic & Research Institutes: University of California, San Diego (UCSD), Johns Hopkins University, Indiana University, Baylor College of Medicine, Rutgers University, Scripps Research, and the Institute for Basic Science (IBS).

  • Government & Healthcare Systems: National Institutes of Health (NIH), Labcorp (Histology Division), and Hackensack Meridian Health.

  • Biotech & Industry Partners: Estuary Biotherapeutics, LumaCyte, and Terrain Life Science.

40 nano-filtered PBS Solution with 4% Paraformaldehyde (PFA)

Jaemin *****

Satisfaction
Quality
Value
Style


It is good.

Satisfaction
Quality Rating
Value Rating
Style Rating
X